Few overheating or already-surging signals — relatively calm. A good stage to observe pre-breakout conditions patiently.
Some risk factors present — volatility, short-term overheating, or thin liquidity. Size and scale in carefully if entering.
Already surged, RSI overheated, extended far from highs, or earnings imminent. Chasing now carries meaningful pullback risk.
DRUG's RSI(14) currently reads 36. RSI compares the size of recent up moves to down moves to flag stretched conditions in either direction. Readings above 70 are typically read as overbought and below 30 as oversold — this one falls in the 'oversold' range. This reading is specific to DRUG on this scan date and can change quickly. → Learn more
ADX currently reads 18. ADX does not indicate direction — it measures trend strength, i.e. how pronounced a trend is (25+ is considered pronounced). Right now DRUG shows +DI and -DI show no clear edge either way, putting it in the 'weak trend' range on ADX. Treat this as one data point on DRUG, not a standalone signal. → Learn more
DRUG's Bollinger Band width is at the 65th percentile (mid-range) of its past year, and the squeeze indicator is not currently active. This measures how tight the recent trading range is relative to where it normally sits. A squeeze is often followed by a volatility expansion in either direction. Treat this as one data point on DRUG, not a standalone signal. → Learn more
DRUG's OBV is currently not showing a clear rise (none), and the up/down volume ratio is 1.3x. OBV (On-Balance Volume) uses the cumulative direction of volume to estimate accumulation or distribution. Treat this as one data point on DRUG, not a standalone signal. → Learn more
DRUG's recent volume is running at 0.5x its usual level. This figure flags whether trading activity has picked up relative to its own recent norm — a reference point for whether order flow is concentrating around this stock. Cross-check this against DRUG's other indicators above before drawing a conclusion. → Learn more
DRUG's change over the last 5 trading days is -6.7%, and over the last 1 trading day is +2.7%. These two numbers show recent short-term direction but say nothing about where the price goes next.
DRUG's current price is 23.1% below its 20-day high. Distance from the recent high is a reference point for how close price is to potential resistance. On this measure it currently falls in the 'distance from high' category. Treat this as one data point on DRUG, not a standalone signal. → Learn more
DRUG's ATR% currently reads 5.6%, a 'daily range' level. ATR (Average True Range) measures the average size of a stock's daily price swings. Cross-check this against DRUG's other indicators above before drawing a conclusion. → Learn more
DRUG's 20-trading-day relative strength versus SPY (S&P 500 ETF) is -16.4%. DRUG underperformed the S&P 500 over this particular window. Cross-check this against DRUG's other indicators above before drawing a conclusion. → Learn more
Stocks holding Stochastic Oversold Reversal reached +15% 36.0% of the time, versus a 29.3% base rate — not a statistically significant difference (1689 cases). Cross-check this against DRUG's other indicators above before drawing a conclusion. → Stochastic Oversold Reversal
Measured (n=6731), the hit-rate for ADX Trend Strengthening (29.5%) was not statistically distinguishable from the base rate (29.3%). Treat this as one data point on DRUG, not a standalone signal. → ADX Trend Strengthening
Stocks holding Weekly Squeeze reached +15% 25.4% of the time, versus a 29.3% base rate — not a statistically significant difference (5281 cases). As with any single metric, weigh this alongside DRUG's full indicator set. → Weekly Squeeze
Among stocks holding Avg Daily Range 4%+, 59.5% reached +15% within 20 trading days — significantly above the full-universe base rate of 29.3% (2502 cases measured). Cross-check this against DRUG's other indicators above before drawing a conclusion. → Avg Daily Range 4%+
Limitations of this page — Automatically calculated, not a stock recommendation. Score is a count of conditions met, not a prediction; base rates are historical measurements only (DRUG diagnostic as of 2026.09.09 14:40).
A history of past monitoring candidates — not investment advice. See the scanner's full track record here.